Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib in adjuvant stage IB-IIA NSCLC
NCT05165355Phase 2Unknown
- Sponsor
- Tongji University
- Start
- Dec 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung carcinoma (NSCLC), sponsored by Tongji University. Primary endpoint: Disease Free Survival rate at 2 years. Status: unknown.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT05165355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165355.